西替利嗪治疗荨麻疹等皮肤病的临床疗效评价

CLINICAL EVALUATION OF CETIRIZINE IN THE TREATMENT OF PATIENTS WITH URTCARIA AND OTHER SKIN DISEASES

西替利嗪是新型的抗组胺药－外周Ｈ１受体拮抗剂。它除能阻断Ｈ１受体外，并对在过敏反应后期起重要作用的嗜酸粒细胞有强大的抑制作用，从而更有效的达到抗组胺效果。临床上广泛用于变态反应性疾病。为了观察西替利嗪在治疗荨麻疹等皮肤病的疗效和安全性，我们对１２０例过敏性及有关瘙痒性皮肤病（急慢性荨麻疹６０例，接触性皮炎、湿疹、皮肤瘙痒症等６０例）进行了随机、单盲、平行性临床验证。结果表明：西替利嗪治疗荨麻疹等皮肤病６０例，其中荨麻疹３０例，总有效率分别为９０％和９３．３％，不良反应发生率８．３％。阿司咪唑（阳性对照）治疗荨麻疹等皮肤病６０例，其中荨麻疹３０例，总有效率为６５％和６３．３％，不良反应发生率８．３％。提示试验组在治疗荨麻疹等皮肤病的疗效明显优于对照组（Ｐ＞０．０５），不良反应发生率无明显差异（Ｐ＜０．０５）。

Cetirizine is a new type of antihistamine drug(peripheral H1 receptor antagonist) It can block H1 receptor and strongly inhibit the activities of eosinocytes which play an important part during the late stage of allergic reaction, thereby offering better theraputic effect.Because of its unique mechanism and safety for use in the clinic,it has been widely applied to the treatment of allergic diseases.To study the efficacy and safety of cetirizine in the treatment of uriticaria and other skin diseases,a randomized single-blind and parallel clinical trial was performed.in 120 patients with urticaria and other allergic skin diseases(acute and cronic urticaria in 60 cases;contact dermatitis,eczema and pruritus in 60 cases)Of 60 cases with urticaria or other diseases treated by cetirizine,30 cases were urticaria.The total efficacy were 90% and 93.3% respectively Adverse effect was 8.3%。Of 60 cases treated with asternizole as positive control 30 cases were urticaria.The total efficacy were 65% and 63.3% respectively Adverse effect was 8. 3% The efficacy of test group was obviously higher than that of the control group(P<0.05),but there was no significant difference in adverse effect(P<0.05)。